Evaluation of the Causes and Disease Processes of Chronic Lung Disease

Pulmonary Disease Clinical Trial

Official title:

Comprehensive Evaluation of the Etiology and Pathogenesis of Chronic Lung Disease (Screening Protocol)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00001183
• Other study ID #: 820032
• Secondary ID: 82-H-0032
• Status: Completed
• Start date: November 18, 1984
• Est. completion date: December 16, 2019

Study information

• Verified date: May 2022
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Chronic lung diseases are disorders associated with abnormalities in any of the structures involved in the process of breathing and bringing oxygen into the lungs and blood. This includes abnormalities in the airways, lungs, blood vessels in and around the lungs, and the tissue covering the lungs (pleura).

The purpose of this research study is to evaluate patients referred to the Cardiovascular and Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to;

1. Develop a better understanding of the causes and disease processes involved in disorders of the lungs

2. Identify patients eligible to participate in other P-CCMB research studies

Description:

The chronic lung diseases are those disorders associated with functional and/or structural derangement to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this project is to permit the comprehensive evaluation of patients referred to the Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other NHLBI protocols. Testing and procedures will only be performed when medically indicated for the purposes of making a diagnosis or obtaining information likely to be useful in the management of the subjects' disease or condition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6564
• Est. completion date: December 16, 2019
• Est. primary completion date: December 16, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 90 Years

Eligibility

• INCLUSION CRITERIA:

Symptoms consistent with pulmonary disease.

May have family history of lung disease.

Patients with diseases of organs with known association with lung disease.

Ranging in age from 7 to 90 years old.

Pregnant and nursing women may participate in minimal risk procedures

EXCLUSION CRITERIA:

Persons with no clinical evidence of lung disease.

Related Conditions & MeSH terms

• Lung Diseases
• Pulmonary Disease

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	N/A-screening protocol	Evaluate	1 Visit

External Links

•   NIH Clinical Center Detailed Web Page